[(2R,3R)-2-(3-bromo-4-methoxyphenyl)-6-methoxy-4-oxo-2,3-dihydrochromen-3-yl] N-(4-methylphenyl)sulfonylcarbamate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: [(2R,3R)-2-(3-bromo-4-methoxyphenyl)-6-methoxy-4-oxo-2,3-dihydrochromen-3-yl] N-(4-methylphenyl)sulfonylcarbamate
• 化学式: C₂₅H₂₂BrNO₈S
• 分子量: 576.4
• InChiKey: FQSGLLNICMDDKT-RPWUZVMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS
  申请人：TRUSTEES OF BOSTON UNIVERSITY

  公开号：US20140050711A1

  公开（公告）日：2014-02-20

  This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.

  本公开提供了一种制备巨核细胞-红细胞祖细胞（MEP）的方法，包括在培养中将干细胞分化为MEP，并在存在芳香烃受体（AhR）激动剂的情况下进行。在某些实施例中，干细胞是多能干细胞。在某些实施例中，MEP共同表达CD41和CD235。在某些实施例中，培养中产生的MEP数量呈指数增长。本公开还提供了通过在存在AhR激动剂的情况下培养MEP来制备红细胞（RBC）的方法。还提供了通过在存在AhR调节剂的情况下培养MEP来制备巨核细胞和/或血小板的方法。在某些实施例中，AhR调节剂是AhR拮抗剂。本公开还提供了每毫升至少含有100万个MEP的组合物，以及至少50%的细胞为MEP的组合物。
• Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
  申请人：Trustees of Boston University

  公开号：US10258600B2

  公开（公告）日：2019-04-16

  Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

  本文提供了调节 AhR 活性的新型制剂，用于抑制癌细胞增殖和肿瘤细胞侵袭及转移的治疗组合物及其方法。这些制剂包括式（I）和式（II）的 AhR 抑制剂或非组成型 AhR 激动剂，用于抑制癌细胞生长和表征肿瘤转移的参数，如肿瘤细胞侵袭性。
• Production of red blood cells and platelets from stem cells
  申请人：Boston Medical Center Corporation

  公开号：US10544393B2

  公开（公告）日：2020-01-28

  This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs.

  本公开提供了制造巨核细胞-红细胞祖细胞（MEP）的方法，包括在芳基烃受体（AhR）激动剂存在下，在培养过程中将干细胞分化成MEP。在某些实施方案中，干细胞是多能干细胞。在某些实施方案中，MEP共同表达CD41和CD235。在某些实施方案中，培养中产生的MEP数量呈指数增长。还提供了在 AhR 激动剂存在下培养 MEP 制造红细胞（RBC）的方法。还提供了制造巨核细胞和/或血小板的方法，包括在有 AhR 调节剂存在的情况下培养 MEP。在某些实施方案中，AhR 调节剂是 AhR 拮抗剂。本公开还提供了包含每毫升至少 100 万个巨核细胞的组合物，以及其中至少 50% 的细胞为巨核细胞的组合物。
• ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS
  申请人：Sherr David H.

  公开号：US20130281525A1

  公开（公告）日：2013-10-24

  Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
• US9074186B2
  申请人：——

  公开号：US9074186B2

  公开（公告）日：2015-07-07